Expression and molecular profiles of the AlkB family in ovarian serous carcinoma.
AlkB family
expression profiles
infiltrating immune cells
methylation
ovarian serous carcinoma
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
19 03 2021
19 03 2021
Historique:
received:
05
01
2021
accepted:
08
02
2021
pubmed:
22
3
2021
medline:
30
7
2021
entrez:
21
3
2021
Statut:
ppublish
Résumé
AlkB family of Fe (II) and α-ketoglutarate-dependent dioxygenases plays essential roles in development of ovarian serous carcinoma (OV). However, the molecular profiles of AlkB family in OV have not been clarified. The results indicated that the expression of ALKBH1/3/5/8 and FTO was lower in OV patients while ALKBH2/4/6/7 expression was higher. There was a strong correlation between ALKBH5/7 and pathological stage of OV patients. Kaplan-Meier plotter revealed that OV patients with high ALKBH4 level showed longer overall survival (OS). However, patients with high levels of ALKBH5/6 and FTO showed shorter OS and progression-free survival (PFS). Genetic alterations using cBioPortal revealed that the alteration rates of FTO were the highest. We also found that the functions of AlkB family were linked to several cancer-associated signaling pathways, including chemokine receptor signaling. TIMER database indicated that the AlkB family had a strong relationship with the infiltration of six types of immune cells (macrophages, neutrophils, CD8+ T-cells, B-cells, CD4+ T-cells and dendritic cells). Next, DiseaseMeth databases revealed that the global methylation levels of ALKBH1/2/3/4/5/6/7/8 and FTO were all lower in OV patients. Thus, our findings will enhance the understanding of AlkB family in OV pathology, and provide novel insights into AlkB-targeted therapy for OV patients.
Identifiants
pubmed: 33744868
pii: 202716
doi: 10.18632/aging.202716
pmc: PMC8064172
doi:
Substances chimiques
AlkB Enzymes
EC 1.14.11.33
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9679-9692Références
Cancer Sci. 2013 Mar;104(3):321-7
pubmed: 23279696
Nat Rev Cancer. 2017 Apr;17(4):209-222
pubmed: 28233802
Mol Cancer. 2020 Mar 12;19(1):53
pubmed: 32164750
Front Oncol. 2020 Feb 26;10:115
pubmed: 32175271
Front Oncol. 2020 Sep 29;10:531790
pubmed: 33117676
Cell Metab. 2017 Jul 5;26(1):49-70
pubmed: 28683294
Front Cell Dev Biol. 2020 Aug 11;8:782
pubmed: 32850871
Front Cell Dev Biol. 2020 Aug 11;8:758
pubmed: 32850861
Cell. 2018 Nov 15;175(5):1228-1243.e20
pubmed: 30392959
Nucleic Acids Res. 2017 Jan 4;45(D1):D888-D895
pubmed: 27899673
Front Oncol. 2020 Dec 07;10:599915
pubmed: 33364196
Expert Opin Emerg Drugs. 2019 Dec;24(4):239-253
pubmed: 31755325
Int J Mol Sci. 2018 Jun 30;19(7):
pubmed: 29966369
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595
pubmed: 30321428
J Exp Clin Cancer Res. 2019 Apr 15;38(1):163
pubmed: 30987661
Front Oncol. 2020 May 29;10:718
pubmed: 32547941
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205
pubmed: 31114916
Nucleic Acids Res. 2019 Jul 2;47(W1):W556-W560
pubmed: 31114875
Cell Oncol (Dordr). 2020 Aug;43(4):515-538
pubmed: 32418122
Genome Biol. 2019 Sep 2;20(1):185
pubmed: 31477170
Nucleic Acids Res. 2015 Jan;43(1):373-84
pubmed: 25452335
Nature. 2019 Feb;566(7743):270-274
pubmed: 30728504
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W214-20
pubmed: 20576703
Mol Ther Nucleic Acids. 2020 Mar 6;19:405-412
pubmed: 31887551
Cancers (Basel). 2020 May 29;12(6):
pubmed: 32485873
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Aging (Albany NY). 2020 Sep 20;12(18):18453-18475
pubmed: 32950970
Sci Adv. 2018 Oct 03;4(10):eaar8263
pubmed: 30306128
Cancer Cell. 2017 Apr 10;31(4):591-606.e6
pubmed: 28344040
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
J Exp Clin Cancer Res. 2020 Sep 29;39(1):203
pubmed: 32993738
Mol Cancer. 2020 Aug 10;19(1):123
pubmed: 32772918
Front Cell Dev Biol. 2020 Oct 14;8:561804
pubmed: 33163485
Mol Cancer. 2019 Dec 4;18(1):176
pubmed: 31801551
Front Oncol. 2020 Jan 21;9:1537
pubmed: 32039018
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813239
Front Bioeng Biotechnol. 2018 Jul 13;6:89
pubmed: 30062093
Biochem Pharmacol. 2020 Dec;182:114258
pubmed: 33017575
Orv Hetil. 2005 Mar 20;146(12):559-63
pubmed: 15853065
Cancer Cell. 2020 Jul 13;38(1):79-96.e11
pubmed: 32531268
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
EBioMedicine. 2019 Sep;47:184-194
pubmed: 31492560
J Cell Mol Med. 2020 Jun;24(11):6137-6148
pubmed: 32329191
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Nucleic Acids Res. 2020 Apr 17;48(7):3816-3831
pubmed: 31996915